SnapShot: Cancer Immunotherapy with Oncolytic Viruses

Cell
Shashi A GujarJean-Simon Diallo

Abstract

Oncolytic viruses (OVs) preferentially infect and kill cancer cells without harming normal cells. OVs can revert cancer-associated immune suppression and initiate clinically meaningful antitumor immune responses. OVs and their resultant immunological events can act at both primary and metastatic sites. Thus, OVs can be exploited for cancer gene therapies and immunotherapies alone or in combination with other interventions, including immune checkpoint blockade.

Citations

Jul 3, 2020·Nature Reviews. Drug Discovery·Erin A Kimbrel, Robert Lanza
May 7, 2020·Frontiers in Oncology·Lizhi LiJian Ma
May 24, 2020·Communications Biology·Rozanne ArulanandamJean-Simon Diallo
Jun 4, 2019·Frontiers in Immunology·Zenan WangZhaoming Ye
Jan 7, 2021·Stem Cell Reviews and Reports·Hesam Saghaei BagheriReza Rahbarghazi
Jan 28, 2021·Cell Biology International·Guang-Lin LeiPeng-Hui Yang
Oct 15, 2020·International Journal of Molecular Sciences·Jana de SostoaDenis Migliorini
Jul 20, 2020·Biochemical Pharmacology·Xinran Li, Xin-Hua Feng
May 1, 2021·Viruses·Vishnupriyan KumarShashi Gujar
Nov 20, 2020·Molecular Therapy Oncolytics·Fanny TzelepisJean-Simon Diallo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Cell eTOC

Cell is a scientific journal publishing research across a broad range of disciplines within the life sciences field. Discover the latest research from Cell here.